Transcriptomic Analysis Reveals Cell Apoptotic Signature Modified by Heparanase in Melanoma Cells

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2019 May 3

PMID 31044520

Citations 7

Authors

Tianyi Song

Dorothe Spillmann

Affiliations

Soon will be listed here.

Abstract

Heparanase has been implicated in many pathological conditions, especially inflammation and cancer, attributed to its degradation of heparan sulfate, a crucial component maintaining the integrity of the extracellular matrix. By silencing the heparanase gene (HPSE) in MDA-MB-435s melanoma cells, we investigated the impact of this protein on gene transcription. Transcriptome sequencing yielded a list of 279 differentially expressed genes, of which 140 were up-regulated and 239 down-regulated. The 140 up-regulated genes were classified into a substantial set of gene ontology defined functions, for example, positive regulation of cell death, apoptotic process, response to cytokine, while 239 down-regulated genes classify only into the two categories: nucleosome and nucleosome assembly. Our focus was drawn to an array of 28 pro-apoptotic genes regulated by heparanase: real-time PCR experiments further validated up-regulation of EGR1, TXNIP, AXL, CYR61, LIMS2 and TNFRSF12A by at least 1.5-fold, among which EGR1, CYR61, and TNFRSF12A were confirmed on protein level. We demonstrated significantly increased apoptotic cells by TUNEL staining upon HPSE silencing, mediated by activation of caspase 3/PARP1 pathway. The pro-apoptotic gene expression and observation of apoptosis were extended to another melanoma cell line, MV3 cells, thus consolidating the anti-apoptosis effect of heparanase in melanoma cells.

Citing Articles

is Downregulated in Osteosarcoma and Inhibits Cell Growth and Migration.

Su C, Cai X, Xu T, Wu Y, Wang L, Chen P J Oncol. 2022; 2022:4811260.

PMID: 36276291 PMC: 9584710. DOI: 10.1155/2022/4811260.

The Heparanase Regulatory Network in Health and Disease.

Mayfosh A, Nguyen T, Hulett M Int J Mol Sci. 2021; 22(20).

PMID: 34681753 PMC: 8541136. DOI: 10.3390/ijms222011096.

Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer.

Zahavi T, Salmon-Divon M, Salgado R, Elkin M, Hermano E, Rubinstein A NPJ Breast Cancer. 2021; 7(1):67.

PMID: 34050190 PMC: 8163849. DOI: 10.1038/s41523-021-00277-x.

[Heparanase promotes trans-endothelial migration of hepatocarcinoma cells by inducing apoptosis of microvascular endothelial cells].

Chen X, Ye R, Dai D, Wu Y, Yu Y, Cheng B Nan Fang Yi Ke Da Xue Xue Bao. 2020; 40(8):1065-1071.

PMID: 32895190 PMC: 7429165. DOI: 10.12122/j.issn.1673-4254.2020.08.01.

Significance of host heparanase in promoting tumor growth and metastasis.

Zhang G, Gutter-Kapon L, Ilan N, Batool T, Singh K, Digre A Matrix Biol. 2020; 93:25-42.

PMID: 32534153 PMC: 7704762. DOI: 10.1016/j.matbio.2020.06.001.

References

Gotte M . Syndecans in inflammation. FASEB J. 2003; 17(6):575-91. DOI: 10.1096/fj.02-0739rev. View

Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, PECKER I . Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res. 2001; 61(12):4655-9. View

Ogishima T, Shiina H, Breault J, Tabatabai L, Bassett W, Enokida H . Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res. 2005; 11(3):1028-36. View

Ostrovsky O, Grushchenko-Polaq A, Beider K, Mayorov M, Canaani J, Shimoni A . Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies. Oncogenesis. 2018; 7(6):51. PMC: 6023935. DOI: 10.1038/s41389-018-0060-8. View

Akbarshahi H, Axelsson J, Said K, Malmstrom A, Fischer H, Andersson R . TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated. J Transl Med. 2011; 9:219. PMC: 3286488. DOI: 10.1186/1479-5876-9-219. View

Cassinelli G, Lanzi C, Tortoreto M, Cominetti D, Petrangolini G, Favini E . Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem Pharmacol. 2013; 85(10):1424-32. DOI: 10.1016/j.bcp.2013.02.023. View

Rabelink T, van den Berg B, Garsen M, Wang G, Elkin M, van der Vlag J . Heparanase: roles in cell survival, extracellular matrix remodelling and the development of kidney disease. Nat Rev Nephrol. 2017; 13(4):201-212. DOI: 10.1038/nrneph.2017.6. View

Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I, Elkin M . Role of endothelial heparanase in delayed-type hypersensitivity. Blood. 2005; 107(9):3609-16. PMC: 1444937. DOI: 10.1182/blood-2005-08-3301. View

Timar J, Lapis K, Dudas J, Sebestyen A, Kopper L, Kovalszky I . Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Semin Cancer Biol. 2002; 12(3):173-86. DOI: 10.1016/S1044-579X(02)00021-4. View

10.

Liu X, Fang H, Chen H, Jiang X, Fang D, Wang Y . An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PLoS One. 2012; 7(6):e38659. PMC: 3376136. DOI: 10.1371/journal.pone.0038659. View

11.

Ogishima T, Shiina H, Breault J, Terashima M, Honda S, Enokida H . Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. Oncogene. 2005; 24(45):6765-72. DOI: 10.1038/sj.onc.1208811. View

12.

Shafat I, Weyl Ben-Arush M, Issakov J, Meller I, Naroditsky I, Tortoreto M . Pre-clinical and clinical significance of heparanase in Ewing's sarcoma. J Cell Mol Med. 2010; 15(9):1857-64. PMC: 3056168. DOI: 10.1111/j.1582-4934.2010.01190.x. View

13.

Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D . PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Res. 2016; 45(D1):D183-D189. PMC: 5210595. DOI: 10.1093/nar/gkw1138. View

14.

Song T, Spillmann D . Transcriptomic analysis reveals cell apoptotic signature modified by heparanase in melanoma cells. J Cell Mol Med. 2019; 23(7):4559-4568. PMC: 6584584. DOI: 10.1111/jcmm.14349. View

15.

Mi H, Muruganujan A, Casagrande J, Thomas P . Large-scale gene function analysis with the PANTHER classification system. Nat Protoc. 2013; 8(8):1551-66. PMC: 6519453. DOI: 10.1038/nprot.2013.092. View

16.

Lerner I, Hermano E, Zcharia E, Rodkin D, Bulvik R, Doviner V . Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest. 2011; 121(5):1709-21. PMC: 3083784. DOI: 10.1172/JCI43792. View

17.

Reiland J, Kempf D, Roy M, Denkins Y, Marchetti D . FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Neoplasia. 2006; 8(7):596-606. PMC: 1601937. DOI: 10.1593/neo.06244. View

18.

Hulett M, Freeman C, Hamdorf B, Baker R, Harris M, Parish C . Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med. 1999; 5(7):803-9. DOI: 10.1038/10525. View

19.

Korch C, Hall E, Dirks W, Ewing M, Faries M, Varella-Garcia M . Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line. Int J Cancer. 2017; 142(3):561-572. PMC: 5762610. DOI: 10.1002/ijc.31067. View

20.

Wang F, Jia J, Lal N, Zhang D, Chiu A, Wan A . High glucose facilitated endothelial heparanase transfer to the cardiomyocyte modifies its cell death signature. Cardiovasc Res. 2016; 112(3):656-668. PMC: 5157136. DOI: 10.1093/cvr/cvw211. View